Emerging anticoagulant strategies

Blood

Volumn 129, Issue 2, 2017, Pages 147-154

  Fredenburgh, James C ^a,b   Gross, Peter L ^a,b   Weitz, Jeffrey I ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; POLYPHOSPHATE; THROMBIN; THROMBOPLASTIN;

ANTICOAGULATION; ARTERY INJURY; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; THROMBOCYTE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR XI; FACTOR XII; HUMANS; THROMBOSIS;

EID: 85016259692     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-09-692996     Document Type: Review

References (70)

1. Wendelboe AM, Raskob GE. Global burden of thrombosis: Epidemiologic aspects. Circ Res. 2016;118(9):1340-1347.
2. Diamond SL. Systems analysis of thrombus formation. Circ Res. 2016;118(9):1348-1362.
3. Casa LD, Deaton DH, Ku DN. Role of high shear rate in thrombosis. J Vasc Surg. 2015;61(4): 1068-1080.
4. Agnelli G, Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost. 2006; 4(9):1886-1890.
5. Weitz JI. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. Thromb Haemost. 2014; 112(5):924-931.
6. Boonyawat K, Crowther MA. Aspirin in secondary prevention of recurrent venous thromboembolism. J Thromb Thrombolysis. 2015;39(3):392-394.
7. Weitz JI. Factor XI and factor XII as targets for new anticoagulants. Thromb Res. 2016; 141(Suppl 2):S40-S45.
8. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819-835.
9. Brill A, Fuchs TA, Chauhan AK, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117(4):1400-1407.
10. Geddings JE, Hisada Y, Boulaftali Y, et al. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost. 2016;14(1):153-166.
11. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10(1):136-144.
12. Smith SA, Morrissey JH. 2013 scientific sessions Sol Sherry distinguished lecture in thrombosis: polyphosphate: a novel modulator of hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2015;35(6):1298-1305.
13. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem. 2002;277(21): 18322-18333.
14. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science. 1991;253(5022):909-912.
15. Ardissino D, Merlini PA, Bauer KA, et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood. 2003;102(8): 2731-2735.
16. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19.
17. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271-281.
18. Renné T, Oschatz C, Seifert S, et al. Factor XI deficiency in animal models. J Thromb Haemost. 2009;7(Suppl 1):79-83.
19. Long AT, Kenne E, Jung R, Fuchs TA, Renné T. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost. 2016;14(3):427-437.
20. van Montfoort ML, Meijers JC. Recent insights into the role of the contact pathway in thrombo-inflammatory disorders. Hematology (Am Soc Hematol Educ Program). 2014;2014(1):60-65.
21. Maas C, Oschatz C, Renné T. The plasma contact system 2.0. Semin Thromb Hemost. 2011;37(4):375-381.
22. Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it? J Thromb Haemost. 2015;13(Suppl 1):S72-S81.
23. van der Meijden PE, Munnix IC, Auger JM, et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood. 2009;114(4):881-890.
24. Maas C, Govers-Riemslag JW, Bouma B, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest. 2008;118(9): 3208-3218.
25. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA. 2007;104(15):6388-6393.
26. Faxälv L, Boknäs N, Ström JO, et al. Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII. Blood. 2013;122(23):3818-3824.
27. Gailani D. Future prospects for contact factors as therapeutic targets. Hematology (Am Soc Hematol Educ Program). 2014;2014(1):52-59.
28. McFadyen JD, Jackson SP. Differentiating haemostasis from thrombosis for therapeutic benefit. Thromb Haemost. 2013;110(5):859-867.
29. Chan NC, Eikelboom JW, Weitz JI. Evolving treatments for arterial and venous thrombosis: Role of the direct oral anticoagulants. Circ Res. 2016;118(9):1409-1424.
30. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
31. Kirchhof P, Benussi S, Kotecha D, et al; Authors/ Task Force Members; Document Reviewers:. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO) [published online ahead of print 27 June 2016]. Eur Heart J. doi:10.1093/eurheartj/ehw210.
32. Hart RG, Diener HC, Coutts SB, et al; Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014; 13(4):429-438.
33. Simes J, Becattini C, Agnelli G, et al; INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130(13): 1062-1071.
34. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.
35. Alamneh EA, Chalmers L, Bereznicki LR. Suboptimal use of oral anticoagulants in atrial fibrillation: Has the introduction of direct oral anticoagulants improved prescribing practices? Am J Cardiovasc Drugs. 2016;16(3):183-200.
36. Gailani D, Bane CE, Gruber A. Factor XI and contact activation as targets for antithrombotic therapy. J Thromb Haemost. 2015;13(8): 1383-1395.
37. Key NS. Epidemiologic and clinical data linking factors XI and XII to thrombosis. Hematology (Am Soc Hematol Educ Program). 2014;2014(1): 66-70.
38. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood. 2011;118(19): 5302-5311.
39. Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123(13):2102-2107.
40. Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010;116(19): 3981-3989.
41. Matafonov A, Leung PY, Gailani AE, et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood. 2014;123(11): 1739-1746.
42. Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010;116(22):4684-4692.
43. Crosby JR, Marzec U, Revenko AS, et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol. 2013;33(7):1670-1678.
44. David T, Kim YC, Ely LK, et al. Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis. Sci Transl Med. 2016;8(353):353ra112.
45. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009;113(4): 936-944.
46. Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 2014;6(222):222ra17.
47. Woodruff RS, Xu Y, Layzer J, Wu W, Ogletree ML, Sullenger BA. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost. 2013;11(7): 1364-1373.
48. Deng H, Bannister TD, Jin L, et al. Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole arginine. Bioorg Med Chem Lett. 2006;16(11):3049-3054.
49. Wong PC, Crain EJ, Watson CA, Schumacher WA. A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis. 2011;32(2):129-137.
50. Quan ML, Wong PC, Wang C, et al. Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors. J Med Chem. 2014; 57(3):955-969.
51. Al-Horani RA, Ponnusamy P, Mehta AY, Gailani D, Desai UR. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J Med Chem. 2013;56(3):867-878.
52. Al-Horani RA, Desai UR. Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides. J Med Chem. 2014;57(11):4805-4818.
53. Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathu JN, Morrissey JH. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood. 2014;124(22): 3183-3190.
54. Zhu S, Travers RJ, Morrissey JH, Diamond SL. FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/ tissue factor surfaces under flow. Blood. 2015; 126(12):1494-1502.
55. Jain S, Pitoc GA, Holl EK, et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci USA. 2012;109(32): 12938-12943.
56. Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost. 2009;7(Suppl 1):84-87.
57. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342(10):696-701.
58. Cushman M, O’Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood. 2009;114(14):2878-2883.
59. Siegerink B, Govers-Riemslag JW, Rosendaal FR, Ten Cate H, Algra A. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation. 2010; 122(18):1854-1861.
60. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood. 2006;108(13):4045-4051.
61. Salomon O, Steinberg DM, Dardik R, et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost. 2003;1(4):658-661.
62. Koster T, Rosendaal FR, Briët E, Vandenbroucke JP. John Hageman’s factor and deep-vein thrombosis: Leiden thrombophilia Study. Br J Haematol. 1994;87(2):422-424.
63. Zeerleder S, Schloesser M, Redondo M, et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency–a study on 73 subjects from 14 Swiss families. Thromb Haemost. 1999;82(4):1240-1246.
64. Yau JW, Stafford AR, Liao P, et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater. 2012;8(11):4092-4100.
65. Jaffer IH, Stafford AR, Fredenburgh JC, Whitlock RP, Chan NC, Weitz JI. Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc. 2015;4(8):e002322.
66. Rx, a novel and specific antisense inhibitor of factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers [abstract]. Blood. 2011; 118(21). Abstract 209.
67. Büller HR, Bethune C, Bhanot S, et al; FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232-240.
68. Kearon C. Natural history of venous thromboembolism. Circulation. 2003; 107(23 Suppl 1):I22-I30.
69. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014; 12(3):320-328.
70. Eikelboom JW, Connolly SJ, Brueckmann M, et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206-1214.